BMJ Best Practice

参考文献

关键文献

Reibel J. Prognosis of oral premalignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003;14:47-62.

Sciubba JJ. Oral leukoplakia. Crit Rev Oral Biol Med. 1995;6:147-160.

参考文章

1.  Kramer IR, Lucas RB, Pindborg JJ, et al. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol. 1978;46:518-539.

2.  Axell T, Holmstrup P, Kramer IRH, et al. International seminar on oral leukoplakia and associated lesions related to tobacco habits. Community Dent Oral Epidemiol. 1984;12:145-154.

3.  Axell T, Pindborg JJ, Smith CJ, et al. Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med. 1996;25:49-54.

4.  Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575-580.

5.  Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol. 1986;61:373-381.

6.  Mehta FS, Pindborg JJ, Gupta PC, et al. Epidemiologic and histologic study of oral cancer and leukoplakia among 50,915 villagers in India. Cancer. 1969;24:832-849.

7.  Mehta, FS, Gupta PC, Daftary PK, et al. An epidemiologic study of oral cancer and precancerous conditions among 101,761 villagers in Maharashtra, India. Int J Cancer. 1972;10:134-141.

8.  Krogh P, Hald B, Holmstrup P. Possible mycological etiology of oral mucosal cancer: catalytic potential of infecting Candida albicans and other yeasts in production of N-nitrosobenzylmethylamine. Carcinogenesis. 1987;8:1543-1548.

9.  Baric JM, Altman JE, Feldman RS, et al. Influence of cigarette, pipe, and cigar smoking, removable partial dentures, and age on oral leukoplakia. Oral Surg Oral Med Oral Pathol. 1982;54:424-429.

10.  Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52:195-215.

11.  Liu W, Shen XM, Liu Y, et al. Malignant transformation of oral verrucous leukoplakia: a clinicopathologic study of 53 cases. J Oral Pathol Med. 2011;40:312-316.

12.  Poh CF, Zhang L, Lam WL, et al. A high frequency of allelic loss in oral verrucous lesions may explain malignant risk. Lab Invest. 2001;81:629-634.

13.  Reibel J. Prognosis of oral premalignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003;14:47-62.

14.  Kawanishi S, Hiraku Y, Pinlaor S, et al. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-mediated carcinogenesis. Biol Chem. 2006;387:365-372.

15.  Zhang L, Rosin MP. Loss of heterozygosity: a potential tool in management of oral premalignant lesions? J Oral Pathol Med. 2001;30:513-520.

16.  Warnakulasuriya S, Reibel J, Bouquot J, et al. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 2008;37:127-133.

17.  Thomas G, Hashibe M, Jacob BJ, et al. Risk factors for multiple oral premalignant lesions. Int J Cancer. 2003;107:285-291.

18.  Dietrich T, Reichart PA, Scheifele C. Clinical risk factors of oral leukoplakia in a representative sample of the US population. Oral Oncol. 2004;40:158-163.

19.  Fisher MA, Bouquot JE, Shelton BJ. Assessment of risk factors for oral leukoplakia in West Virginia. Community Dent Oral Epidemiol. 2005;33:45-52.

20.  Jaber MA, Porter SR, Scully C, et al. Role of alcohol in non-smokers and tobacco in non-drinkers in the aetiology of oral epithelial dysplasia. Int J Cancer. 1998;77:333-336.

21.  Warnakulasuriya S, Parkkila S, Nagao T, et al. Demonstration of ethanol-induced protein adducts in oral leukoplakia (pre-cancer) and cancer. J Oral Pathol Med. 2008;37:157-165.

22.  Piscopo M, Campisi G, Colella G, et al. H3 and H3.3 histone mRNA amounts and ratio in oral squamous cell carcinoma and leukoplakia. Oral Dis. 2006;12:130-136.

23.  Petti S, Scully C. Association between different alcoholic beverages and leukoplakia among non- to moderate-drinking adults: a matched case-control study. Eur J Cancer. 2006;42:521-527.

24.  Maserejian NN, Joshipura KJ, Rosner BA, et al. Prospective study of alcohol consumption and risk of oral premalignant lesions in men. Cancer Epidemiol Biomarkers Prev. 2006;15:774-781.

25.  Jacob BJ, Straif K, Thomas G, et al. Betel quid without tobacco as a risk factor for oral precancers. Oral Oncol. 2004;40:697-704.

26.  Yen AM, Chen SC, Chang SH, et al. The effect of betel quid and cigarette on multistate progression of oral pre-malignancy. J Oral Pathol Med. 2008;37:417-422.

27.  Ariyawardana A, Sitheeque MA, Ranasinghe AW, et al. Prevalence of oral cancer and pre-cancer and associated risk factors among tea estate workers in central Sri Lanka. J Oral Pathol Med. 2007;36:581-587.

28.  Takeshima M, Saitoh M, Kusano K, et al. High frequency of hypermethylation of p14, p15 and p16 in oral pre-cancerous lesions associated with betel-quid chewing in Sri Lanka. J Oral Pathol Med. 2008;37:475-479.

29.  Hsieh CH, Chang JW, Hsieh JJ, et al. Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area. Head Neck. 2011;33:1758-1764.

30.  Krogh P, Holmstrup P, Thorn JJ, et al. Yeast species and biotypes associated with oral leukoplakia and lichen planus. Oral Surg Oral Med Oral Pathol. 1987;63:48-54.

31.  Krogh P, Holmstrup P, Vedtofte P, et al. Yeast organisms associated with human oral leukoplakia. Acta Derm Venereol Suppl (Stockh). 1986;121:51-55.

32.  Holmstrup P, Bessermann M. Clinical, therapeutic, and pathogenic aspects of chronic oral multifocal candidiasis. Oral Surg Oral Med Oral Pathol. 1983;56:388-395.

33.  Barrett AW, Kingsmill VJ, Speight PM. The frequency of fungal infection in biopsies of oral mucosal lesions. Oral Dis. 1998;4:26-31.

34.  Majumder M, Sikdar N, Paul RR, et al. Increased risk of oral leukoplakia and cancer among mixed tobacco users carrying XRCC1 variant haplotypes and cancer among workers carrying two risk genotypes: one on each of two loci, GSTM3 and XRCC1 (Codon 280). Cancer Epidemiol Biomarkers Prev. 2005;14:2106-2112.

35.  King GN, Healy CM, Glover MT, et al. Prevalence and risk factors associated with leukoplakia, hairy leukoplakia, erythematous candidiasis, and gingival hyperplasia in renal transplant recipients. Oral Surg Oral Med Oral Pathol. 1994;78:718-726.

36.  Hernandez G, Arriba L, Jimenez C, et al. Rapid progression from oral leukoplakia to carcinoma in an immunosuppressed liver transplant recipient. Oral Oncol. 2003;39:87-90.

37.  Auluck A. Dyskeratosis congenita. Report of a case with literature review. Med Oral Patol Oral Cir Bucal. 2007;12:E369-E373.

38.  Alter B. Aplastic anemia, pediatric aspects. Oncologist. 1996;1:361-366.

39.  Tanaka A, Kumagai S, Nakagawa K, et al. Cole-Engman syndrome associated with leukoplakia of the tongue: a case report. J Oral Maxillofac Surg. 1999;57:1138-1141.

40.  Tekcicek M, Tavil B, Cakar A, et al. Oral and dental findings in children with Fanconi anemia. Pediatr Dent. 2007;29:248-252.

41.  Hakansson N, Floderus B, Gustavsson P, et al. Occupational sunlight exposure and cancer incidence among Swedish construction workers. Epidemiology. 2001;12:552-557.

42.  Perea-Milla Lopez E, Minarro-Del Moral RM, Martinez-Garcia C, et al. Lifestyles, environmental and phenotypic factors associated with lip cancer: a case-control study in southern Spain. Br J Cancer. 2003;88:1702-1707.

43.  Pogoda JM, Preston-Martin S. Solar radiation, lip protection, and lip cancer risk in Los Angeles County women (California, United States). Cancer Causes Control. 1996;7:458-463.

44.  Eversole LR. Papillary lesions of the oral cavity: relationship to human papillomaviruses. J Calif Dent Assoc. 2000;28:922-927.

45.  Sand L, Jalouli J, Larsson PA, et al. Human papilloma viruses in oral lesions. Anticancer Res. 2000;20:1183-1188.

46.  Cianfriglia F, Di Gregorio DA, Cianfriglia C, et al. Incidence of human papillomavirus infection in oral leukoplakia: indications for a viral aetiology. J Exp Clin Cancer Res. 2006;25:21-28.

47.  Dickenson AJ, Currie WJ, Avery BS. Screening for syphilis in patients with carcinoma of the tongue. Br J Oral Maxillofac Surg. 1995;33:319-320.

48.  Michalek AM, Mahoney MC, McLaughlin CC, et al. Historical and contemporary correlates of syphilis and cancer. Int J Epidemiol. 1994;23:381-385.

49.  Petti S, Scully C. The role of the dental team in preventing and diagnosing oral cancer: 5. Alcohol and the role of the dentist in alcohol cessation. Dent Update. 2005;32:454-455;458-460;462.

50.  Shiu MN, Chen TH. Impact of betel quid, tobacco and alcohol on three-stage disease natural history of oral leukoplakia and cancer: implication for prevention of oral cancer. Eur J Cancer Prev. 2004;13:39-45.

51.  Sankaranarayanan R, Fernandez Garrote L, Lence Anta J, et al. Visual inspection in oral cancer screening in Cuba: a case-control study. Oral Oncol. 2002;38:131-136.

52.  Shugars DC, Patton LL. Detecting, diagnosing, and preventing oral cancer. Nurse Pract 1997;22:105, 109-110, 113-115.

53.  Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer. 1975;36:1386-1392.

54.  Wright JM. Oral precancerous lesions and conditions. Semin Dermatol. 1994;13:125-131.

55.  Jaber MA, Porter SR, Gilthorpe MS, et al. Risk factors for oral epithelial dysplasia - the role of smoking and alcohol. Oral Oncol. 1999;35:151-156.

56.  Sankaranarayanan R. Screening for cervical and oral cancers in India is feasible and effective. Natl Med J India. 2005;18:281-284.

57.  Mashberg A, Samit A. Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers. CA Cancer J Clin. 1995;45:328-351.

58.  Liu W, Wang YF, Zhou HW, et al. Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients. BMC Cancer. 2010;10:685.

59.  Yanik EL, Katki HA, Silverberg MJ, et al. Leukoplakia, oral cavity cancer risk, and cancer survival in the US elderly. Cancer Prev Res (Phila). 2015;8:857-863.

60.  Massano J, Regateiro FS, Januario G, et al. Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:67-76.

61.  Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6;963-968.

62.  Braakhuis BJ, Brakenhoff RH, Leemans CR. Head and neck cancer: molecular carcinogenesis. Ann Oncol. 2005;16(suppl 2):ii249-ii250.

63.  Braakhuis BJ, Leemans CR, Brakenhoff RH. Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol. 2005;15:113-120.

64.  Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, et al. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res. 2004;10:3607-3613.

65.  Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727-1730.

66.  Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys. 1989;17:691-694.

67.  Silverman S Jr. Early diagnosis of oral cancer. Cancer. 1988;62(suppl 8):1796-1799.

68.  Mashberg A, Feldman LJ. Clinical criteria for identifying early oral and oropharyngeal carcinoma: erythroplasia revisited. Am J Surg. 1988;156:273-275.

69.  Scully C, Malamos D, Levers BG, et al. Sources and patterns of referrals of oral cancer: role of general practitioners. Br Med J (Clin Res Ed). 1986;293:599-601.

70.  Dimitroulis G, Reade P, Wiesenfeld D. Referral patterns of patients with oral squamous cell carcinoma, Australia. Eur J Cancer B Oral Oncol. 1992;28B:23-27.

71.  Chiesa F, Sala L, Costa L, et al. Excision of oral leukoplakias by CO2 laser on an outpatient basis: a useful procedure for prevention and early detection of oral carcinomas. Tumori. 1986;72:307-312.

72.  Holmstrup P, Vedtofte P, Reibel J, et al. Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med. 2007;36:262-266.

73.  Califano J, Westra WH, Meininger G, et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res. 2000;6:347-352.

74.  Abbey LM, Kaugars GE, Gunsolley JC, et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;80:188-191.

75.  Karabulut A, Reibel J, Therkildsen MH, et al. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med. 1995;24:198-200.

76.  Fischer DJ, Epstein JB, Morton TH, et al. Interobserver reliability in the histopathologic diagnosis of oral premalignant and malignant lesions. J Oral Pathol Med. 2004;33:65-70.

77.  Fischer DJ, Epstein JB, Morton TH Jr, et al. Reliability of histologic diagnosis of clinically normal intraoral tissue adjacent to clinically suspicious lesions in former upper aerodigestive tract cancer patients. Oral Oncol. 2005;41:489-496.

78.  Woolgar JA. Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma. Oral Oncol. 2006;42:229-239.

79.  Lathanasupkul P, Poomsawat S, Punyasingh J. A clinicopathologic study of oral leukoplakia and erythroplakia in a Thai population. Quintessence Int. 2007;38:e448-e455.

80.  Kuffer R, Lombardi T. Premalignant lesions of the oral mucosa: a discussion about the place of oral intraepithelial neoplasia (OIN). Oral Oncol. 2002;38:125-130.

81.  Rethman M, Carpenter W, Cohen EE, et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc. 2010;14:509-520.

82.  Fedele S. Diagnostic aids in the screening of oral cancer. Head Neck Oncol. 2009;1:5.

83.  Sciubba JJ. Improving detection of precancerous and cancerous oral lesions: computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. J Am Dent Assoc. 1999;130:1445-1457.

84.  Scheifele C, Schmidt-Westhausen A, Dietrich T, et al. The sensitivity and specificity of the OralCDx technique: evaluation of 103 cases. Oral Oncol. 2004;40:824-828.

85.  Svirsky JA, Burns JC, Carpenter WM, et al. Comparison of computer-assisted brush biopsy results with follow up scalpel biopsy and histology. Gen Dent. 2002;50:500-503.

86.  Kosicki DM, Riva C, Pajarola GF, et al. Oral CDx brush biopsy - a tool for early diagnosis of oral squamous cell carcinoma [in German]. Schweiz Monatsschr Zahnmed. 2007;117:222-227.

87.  Poate TW, Buchanan JA, Hodgson TA, et al. An audit of the efficacy of the oral brush biopsy technique in a specialist Oral Medicine unit. Oral Oncol. 2004;40:829-834.

88.  Remmerbach TW, Weidenbach H, Hemprich A, et al. Earliest detection of oral cancer using non-invasive brush biopsy including DNA-image-cytometry: report on four cases. Anal Cell Pathol. 2003;25:159-166.

89.  Potter TJ, Summerlin DJ, Campbell JH. Oral malignancies associated with negative transepithelial brush biopsy. J Oral Maxillofac Surg. 2003;61:674-677.

90.  Scheifele C, Schlechte H, Bethke G, et al. Detection of TP53-mutations in brush biopsies from oral leukoplakias [in German]. Mund Kiefer Gesichtschir. 2002;6:410-414.

91.  Remmerbach TW, Mathes SN, Weidenbach H, et al. Noninvasive brush biopsy as an innovative tool for early detection of oral carcinomas [in German]. Mund Kiefer Gesichtschir. 2004;8:229-236.

92.  Maraki D, Becker J, Boecking A. Cytologic and DNA-cytometric very early diagnosis of oral cancer. J Oral Pathol Med. 2004;33:398-404.

93.  Remmerbach TW, Weidenbach H, Muller C, et al. Diagnostic value of nucleolar organizer regions (AgNORs) in brush biopsies of suspicious lesions of the oral cavity. Anal Cell Pathol. 2003;25:139-146.

94.  Zhang L, Cheung KJ Jr, Lam WL, et al. Increased genetic damage in oral leukoplakia from high risk sites: potential impact on staging and clinical management. Cancer. 2001;91:2148-2155.

95.  de Vicente JC, Rodrigo JP, Rodriguez-Santamarta T, et al. Podoplanin expression in oral leukoplakia: tumorigenic role. Oral Oncol. 2013;49:598-603.

96.  Patel V, Leethanakul C, Gutkind JS. New approaches to the understanding of the molecular basis of oral cancer. Crit Rev Oral Biol Med. 2001;12:55-63.

97.  Bremmer JF, Brakenhoff RH, Broeckaert MA, et al. Prognostic value of DNA ploidy status in patients with oral leukoplakia. Oral Oncol. 2011;47:956-960.

98.  Khanna R, Agarwal A, Khanna S, et al. S-phase fraction and DNA ploidy in oral leukoplakia. ANZ J Surg. 2010;80:548-551.

99.  Liu W, Zheng W, Xie J, et al. Identification of genes related to carcinogenesis of oral leukoplakia by oligo cancer microarray analysis. Oncol Rep. 2011;26:265-274.

100.  Swinson B, Jerjes W, El-Maaytah M, et al. Optical techniques in diagnosis of head and neck malignancy. Oral Oncol. 2006;42:221-228.

101.  Suhr MA, Hopper C, Jones L, et al. Optical biopsy systems for the diagnosis and monitoring of superficial cancer and precancer. Int J Oral Maxillofac Surg. 2000;29:453-457.

102.  Sharwani A, Jerjes W, Salih V, et al. Assessment of oral premalignancy using elastic scattering spectroscopy. Oral Oncol. 2006;42:343-349.

103.  Westra WH, Sidransky D. Fluorescence visualization in oral neoplasia: shedding light on an old problem. Clin Cancer Res. 2006;12:6594-6597.

104.  Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357-362.

105.  Oh ES, Laskin DM. Efficacy of the ViziLite system in the identification of oral lesions. J Oral Maxillofac Surg. 2007;65:424-426.

106.  Epstein JB, Gorsky M, Lonky S, et al. The efficacy of oral lumenoscopy (ViziLite) in visualizing oral mucosal lesions. Spec Care Dentist. 2006;26:171-174.

107.  Lane PM, Gilhuly T, Whitehead P, et al. Simple device for the direct visualization of oral-cavity tissue fluorescence. J Biomed Opt. 2006;11:024006.

108.  Poh CF, Ng SP, Williams PM, et al. Direct fluorescence visualization of clinically occult high-risk oral premalignant disease using a simple hand-held device. Head Neck. 2007;29:71-76.

109.  Poh CF, Zhang L, Anderson DW, et al. Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin Cancer Res. 2006;12:6716-6722.

110.  Kramer IR. Oral leukoplakia. J R Soc Med. 1980;73:765-767.

111.  Pindborg JJ, Roed-Petersen B, Renstrup G. Role of smoking in floor of mouth leukoplakias. J Oral Pathol. 1972;1:22-29.

112.  Cawson RA. Leukoplakia and oral cancer. Proc R Soc Med. 1969;62:610-614.

113.  Ismail SB, Kumar SKS, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007;49:89-106.

114.  Lopez-Labady J, Viaalrroel-Dorrego M, Gonzalez N, et al. Oral manifestations of systemic and cutaneous lupus erythematosus in a Venezuelan population. J Oral Pathol Med. 2007;36:524-527.

115.  Burge SM, Frith PA, Juniper RP, et al. Mucosal involvement in systemic and chronic cutaneous lupus erythematosus. Br J Dermatol. 1989;121:727-741.

116.  Karjalainen TK, Tomich CE. A histopathologic study of oral mucosal lupus erythematosus. Oral Surg Oral Med Oral Pathol. 1989;67:547-554.

117.  Serpico R, Pannone G, Santoro A, et al. Report of a case of discoid lupus erythematosus localized to the oral cavity: immunofluorescence findings. Int J Immunopathol Pharmacol. 2007;20:651-653.

118.  van der Waal I, Axell T. Oral leukoplakia: a proposal for uniform reporting. Oral Oncol. 2002;38:521-526.

119.  Lodi G, Porter S. Management of potentially malignant disorders: evidence and critique. J Oral Pathol Med. 2008;37:63-69.

120.  Schepman KP, van der Meij EH, Smeele LE, et al. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol. 1998;34:270-275.

121.  Saito T, Sugiura C, Hirai A, et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. Int J Oral Maxillofac Surg. 2001;30:49-53.

122.  Lodi G, Sardella A, Bez C, et al. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev. 2006;(4):CD001829.

123.  Holmstrup P, Vedtofte P, Reibel J, et al. Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2006;42:461-474.

124.  Girard KR, Strahs GR, Chung B. Panoral verrucous dysplasia: report of a case treated with split-thickness skin graft. Oral Surg Oral Med Oral Pathol. 1980;50:124-126.

125.  Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315:1501-1505.

126.  Sankaranarayanan R, Mathew B, Varghese C. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol.1997;33:231-236.

127.  Stich HF, Hornby AP, Mathew B, et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett. 1988;40:93-101.

128.  Elad S, Epstein JB, von Bültzingslöwen I, et al. Topical immunomodulators for management of oral mucosal conditions, a systematic review. Part II: miscellaneous agents. Expert Opin Emerg Drugs. 2011;16:183-202.

129.  William WN Jr, Papadimitrakopoulou VA. Optimizing biomarkers and endpoints in oral cancer chemoprevention trials. Cancer Prev Res (Phila). 2013;6:375-378.

130.  Sciubba JJ. Oral leukoplakia. Crit Rev Oral Biol Med. 1995;6:147-160.

131.  Scully C, Cawson RA. Potentially malignant oral lesions. J Epidemiol Biostat. 1996;1:3-12.

132.  Sciubba JJ, Helman JI. Current management strategies for verrucous hyperkeratosis and verrucous carcinoma. Oral Maxillofac Surg Clin North Am. 2013;25:77-82.

133.  Feller L, Lemmer J. Oral leukoplakia as it relates to HPV infection: a review. Int J Dent. 2012;2012:540561.

使用此内容应接受我们的免责声明